Litigation Details for Janssen Products, L.P. v. Lupin Limited (Fed. Cir. 2014)

Janssen Products, L.P. v. Lupin Limited (Fed. Cir. 2014)

Docket	14-1842	Date Filed	2014-09-19
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	7,700,645
Link to Docket	External link to docket

Details for Janssen Products, L.P. v. Lupin Limited (Fed. Cir. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-19				External link to document

Litigation Summary and Patent Analysis: Janssen Products, L.P. v. Lupin Limited (14-1842)

Last updated: July 23, 2026

Janssen Products, L.P. v. Lupin Limited, No. 14-1842, is a US patent appeal litigation that centers on patent infringement claims asserted by Janssen against Lupin, with the case posture and infringement scope governed by the district court’s Markman claim construction and the asserted patent claims. The appeal record reflects core issues typical of Hatch-Waxman follow-on challenges: whether Lupin’s proposed product infringes the asserted claims as construed, and whether the asserted claims are valid and enforceable.

What is Janssen Products, L.P. v. Lupin Limited, 14-1842 about?

At a high level, No. 14-1842 is an appellate dispute in the US Court of Appeals process arising from an earlier district court decision in a patent infringement action brought by Janssen Products, L.P. against Lupin Limited. The litigation is framed around infringement of one or more US patents tied to a Janssen-branded pharmaceutical product or its active ingredient, formulation, or method-of-use claims, and it involves a competitor seeking approval for a generic or abbreviated version.

What specific drug and patents are at issue in 14-1842?

The prompt identifies only the case caption and docket number (14-1842) without the underlying district court case number, asserted patents, or the FDA ANDA/BLA reference product and drug strength/dosage form. Those details are necessary to produce a complete, accurate litigation summary by patent number, claim construction outcome, and infringement/invalidity holdings. Under the constraints here, no incomplete case-specific patent content can be generated.

What procedural stage does “14-1842” correspond to?

“14-1842” is an appellate docket number, which indicates the dispute reached the appellate stage after a district court decision. Appellate issues typically include:

• Appeal of claim construction (Markman)
• Challenge to legal standards applied to infringement
• Validity issues (anticipation, obviousness, indefiniteness, written description, enablement)
• Disposition of injunction or damages (if any)

What patents does Janssen allege that Lupin infringed in 14-1842?

A patent-by-patent analysis requires the asserted patent list (US publication or patent numbers), claim numbers, and the district court’s infringement and validity findings. The docket-only input provided does not include these identifiers, so a litigation analysis cannot be reliably mapped to specific patent estates, claim themes (composition vs method vs formulation), or potential generic entry barriers.

How did claim construction (Markman) affect infringement in 14-1842?

In generic patent appeals, claim construction is often the pivot point. If the district court construes key claim terms narrowly, an accused product may avoid infringement without reaching validity. If construction is broader, infringement may be found as a matter of law or under the doctrine of equivalents.

A credible analysis requires:

• The district court’s construed terms
• The Federal Circuit’s (or appellate court’s) treatment of those constructions
• How claim construction changed the infringement mapping

No claim construction detail is present in the provided input.

What did the appellate court decide in 14-1842?

A litigation summary must state the disposition: affirmance, reversal, vacatur, remand instructions, and any instructions that affect future proceedings (including whether the court ordered judgment of non-infringement, invalidity, or a new trial). The docket-only input does not include the decision text or outcome.

What is the settlement or injunction status for Janssen vs. Lupin (14-1842)?

Settlement posture and any injunction status are case-specific. In Hatch-Waxman disputes, outcomes can include:

• Consent judgment/settlement with a fixed launch date
• Carve-outs tied to patent expiration
• Stipulated non-infringement/non-validity or covenant not to sue
• Appeals dismissed after settlement

The provided information does not contain settlement dates, license terms, or any injunction references, so no accurate summary can be produced.

Which legal issues were central in Janssen v. Lupin Limited, 14-1842?

Common central issues in ANDA-related patent appeals include:

• Whether Lupin’s proposed product contains every element of the asserted claims
• Whether claim terms require specific structural features, physicochemical parameters, or dosing regimens
• Whether the asserted claims are invalid for lack of novelty or obviousness
• Whether the patents are unenforceable (inequitable conduct) or invalid for specification defects

A case-accurate analysis requires the actual holdings. The input does not include the legal issues as framed by the briefs or the court’s decision.

How strong is Janssen’s patent estate against Lupin for this product?

Evaluating strength requires the set of asserted patents, their remaining term, prosecution history, prior art landscape, and the litigation results (infringement and validity). None of that is available in the prompt beyond the case number.

What generic launch risks exist for Lupin and other ANDA filers after 14-1842?

Generic entry risk depends on:

• Which patents survive appeal
• Whether any remaining patents are still unexpired for the relevant drug/strength/formulation
• Whether the court’s decision triggers an FDA suitability/eligibility pathway under 21 U.S.C. § 355(j)
• Any settlement-based launch dates

Without the decision outcome and asserted-patent scope, launch risk cannot be stated.

What is the Orange Book status tied to 14-1842 litigation?

Orange Book status is specific to the FDA application (ANDA/BLA), reference product, dosage forms, and listed patents. The input does not identify the drug or application number, so the Orange Book mapping cannot be completed.

How does 14-1842 compare with other Janssen vs. generic challenges?

Comparative analysis also requires at least the asserted drug and patent class so that similar cases can be clustered by product family and claim themes. The docket-only input does not permit that comparison.

Key Takeaways

• Janssen Products, L.P. v. Lupin Limited (14-1842) is an appellate-stage patent dispute stemming from an earlier district court decision.
• A complete, patent-by-patent litigation summary requires the asserted patent numbers, the specific district court decision outcome, claim construction results, and the appellate disposition.
• The provided input does not include those case-critical identifiers, so no accurate infringement, validity, or enforcement analysis can be produced.

FAQs

1. What is the docket history for Janssen Products, L.P. v. Lupin Limited, 14-1842?
2. Which claims and claim terms drove the Markman construction in 14-1842?
3. Did the appellate court affirm or reverse the district court’s infringement findings in 14-1842?
4. What Orange Book patents correspond to the product litigated in 14-1842?
5. Were there any stipulations, consent judgments, or settlement terms associated with 14-1842?

References

1. Janssen Products, L.P. v. Lupin Limited, No. 14-1842. (Case docket information).